Nolato announces acquisition of Cope Allman Jaycare

NewsGuard 100/100 Score

As part of the Nolato Group's strategic expansion within medical technology and pharmaceuticals, Nolato has acquired the British company Cope Allman Jaycare for an initial purchase price of SEK 179 million (enterprise value) and a deferred consideration based on earnings up to and including the first quarter of 2014.

Cope Allman Jaycare, which manufactures plastic pharmaceutical packaging, has annual sales of around SEK 270 million. Its customers include a number of major international pharmaceutical companies. The company will be consolidated from 1 April, and will have a positive effect on Nolato's earnings per share 2012.

"Following the acquisition of the US company Contour Plastics, we have worked to add an acquisition in Western Europe," says Hans Porat, President and CEO of Nolato. "Cope Allman Jaycare is a well-managed company, and is a good fit for our growth strategy."

Cope Allman Jaycare has a history within pharmaceutical packaging dating back to 1958, and is expected to record sales for 2012 of around SEK 270 million, with a pro forma EBITDA margin of approximately 14%. The company has 270 employees at its plants in Portsmouth and Newcastle, England.

"Nolato already has a strong position in the Scandinavian pharmaceutical packaging market," adds Christer Wahlquist, President of Nolato Medical. "This acquisition gives us a local presence in the UK, which is an important part of the global pharma­ceutical industry. It also opens doors with a large number of leading international pharmaceutical companies which are existing customers of Cope Allman Jaycare."

The company is being acquired from its current management, which will remain with the business.

Following the acquisition, Nolato will continue to have a strong financial position, with an equity/assets ratio of approximately 47%.

Source:

Nolato

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Common HIV drugs linked to reduced Alzheimer's disease risk